Warning: The NCBI web site requires JavaScript to function. more...
Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells.
Journé F, Kheddoumi N, Chaboteaux C, Duvillier H, Laurent G, Body JJ.
Breast Cancer Res. 2008;10(1):R4. Epub 2008 Jan 11.
Related citations
Bisphosphonates induce breast cancer cell death in vitro.
Fromigue O, Lagneaux L, Body JJ.
J Bone Miner Res. 2000 Nov;15(11):2211-21.
The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T, Williams PJ, Mundy GR, Yoneda T.
Cancer Res. 2001 Jun 1;61(11):4418-24.
Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.
Journe F, Chaboteaux C, Magne N, Duvillier H, Laurent G, Body JJ.
Breast Cancer Res. 2006;8(1):R2. Epub 2005 Dec 12.
Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
Mönkkönen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M, Auriola S, Mönkkönen J.
Anticancer Drugs. 2008 Apr;19(4):391-9.
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.
Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI.
Br J Cancer. 2001 Apr 20;84(8):1126-34.
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC.
Br J Cancer. 2007 Apr 23;96(8):1204-15. Epub 2007 Mar 27.
Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS.
Eur J Pharmacol. 2007 Sep 10;570(1-3):27-37. Epub 2007 Jun 16.
Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.
Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I.
Mol Cancer Ther. 2009 Oct;8(10):2821-32. Epub 2009 Sep 29.
Differential effects of Ca(2+) on bisphosphonate-induced growth inhibition in breast cancer and mesothelioma cells.
Merrell MA, Wakchoure S, Ilvesaro JM, Zinn K, Gehrs B, Lehenkari PP, Harris KW, Selander KS.
Eur J Pharmacol. 2007 Mar 15;559(1):21-31. Epub 2006 Dec 9.
Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells.
Rachner TD, Singh SK, Schoppet M, Benad P, Bornhäuser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC.
Cancer Lett. 2010 Jan 1;287(1):109-16. Epub 2009 Jul 3.
Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines.
Journé F, Magné N, Chaboteaux C, Kinnaert E, Bauss F, Body JJ.
Clin Exp Metastasis. 2006;23(2):135-47. Epub 2006 Aug 16.
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW.
Br J Cancer. 2000 Apr;82(8):1459-68.
Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis.
Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, Seibel MJ, Dunstan CR.
Bone. 2007 Feb;40(2):471-8. Epub 2006 Nov 7.
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs.
Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, Yoneda T.
Breast Cancer Res Treat. 2002 Oct;75(3):249-58.
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR, Yoneda T, Hiraga T.
Semin Oncol. 2001 Apr;28(2 Suppl 6):35-44. Review.
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T, Sasaki A, Dunstan C, Williams PJ, Bauss F, De Clerck YA, Mundy GR.
J Clin Invest. 1997 May 15;99(10):2509-17.
Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid.
Vogt U, Bielawski KP, Bosse U, Schlotter CM.
Oncol Rep. 2004 Nov;12(5):1109-14.
Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC, Journé F, Kheddoumi N, Lagneaux L, Body JJ.
Eur Urol. 2004 Apr;45(4):521-8; discussion 528-9.
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.
Breast Cancer Res. 2008;10(6):R104. Epub 2008 Dec 5.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on